The U.S. Preventive Services Task Force is preparing to issue new guidance that prioritizes human papillomavirus testing over traditional Pap smears for women between the ages of 30 and 65. This proposed shift, which was voted on by panel members at the conclusion of a two-day meeting on Friday, would mark the first time federal guidance steers this demographic toward HPV testing as the primary method. The recommendation also introduces the option for self-administered HPV tests, a development that could significantly alter how millions of women in the United States undergo cervical cancer screening.

Although the recommendation is not yet final, it carries substantial weight in the healthcare system. Under the Affordable Care Act, most private insurers are generally required to cover services recommended by the task force at no cost to patients. The panel, which consists primarily of primary care physicians, voted behind closed doors on the new guidelines. A person familiar with the vote, who spoke on condition of anonymity because they were not authorized to speak publicly, confirmed the outcome of the deliberations.

Cervical cancer is considered one of the most preventable forms of cancer, yet recent research indicates that the United States may be backsliding in its efforts to detect the disease early. The human papillomavirus is responsible for virtually all cervical cancers and is the most common sexually transmitted infection. For decades, the Pap test, which identifies abnormal or precancerous cells on the cervix, has been the standard screening tool. However, HPV tests look for high-risk strains of the virus, which can often be detected before cell abnormalities develop. This allows for longer intervals between screenings.

Medical experts have long noted that HPV testing may be more effective than Pap tests. A 2018 study published in the Journal of the American Medical Association, which included more than 19,000 women, found that HPV tests detect precancerous changes earlier and more accurately than Pap tests. Dr. Sangini Sheth, an associate professor of obstetrics, gynecology and reproductive sciences at Yale School of Medicine, noted that the Pap test alone misses a significant share of abnormalities, catching only roughly 50% to 70% of them. She stated that there is no downside to omitting the Pap test in favor of HPV screening.

The inclusion of self-collection kits represents a major change in how screening is conducted. These tests use a simple vaginal swab rather than a speculum, making the process more comfortable for many patients. Dr. Sheth explained that this option could increase access to screening for individuals who have difficulty tolerating a speculum exam. It also broadens the scenarios in which screening can be offered, such as in mobile health clinics, freestanding labs, or medical specialty offices where pelvic exams are not traditionally performed.

Robert Smith, a cancer epidemiologist and senior vice president of early cancer detection science for the American Cancer Society, emphasized that collecting a specimen is easily accomplished and has equivalent accuracy to physician-collected samples. He noted that some women delay Pap tests due to discomfort or the invasive nature of the exam, particularly when performed by a male doctor. Smith expects that the availability of self-collecting tests will lead to an increase in overall screening rates.

The new guidelines align more closely with recommendations from the American Cancer Society, which began prioritizing HPV testing in 2020. However, differences remain. The cancer society recommends starting screening at age 25 with HPV tests, whereas the task force maintains that women should begin with Pap tests at age 21 and switch to HPV testing at age 30. Additionally, for women using self-collection, the cancer society recommends testing every three years to gather more long-term data, while the task force suggests a five-year interval.

The task force also clarified the criteria for stopping screening at age 65. Women should only cease screening if they have had several negative results in a row over the past decade. Those without this history should continue to be screened. A spokesperson for the American College of Obstetricians and Gynecologists stated that the group is monitoring the process and will evaluate the final proposed changes when they become available. It is not yet clear when the task force’s recommendation will be officially published.

The finalization of these guidelines may involve additional administrative steps. It remains unclear whether Health Secretary Robert F. Kennedy Jr. will need to sign off on the changes or seek modifications. Last year, the Supreme Court ruled that the health secretary has authority over the panel, a decision stemming from a case brought by a Christian-owned business. In September, Kennedy reshaped the panel by naming eight new members. According to documents reviewed by The New York Times, some of these new members own stock in companies that produce drugs and products affected by the group’s decisions. The meeting in question was the committee’s first in more than a year, and a spokesperson for the Department of Health and Human Services did not immediately respond to requests for comment.